StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen collaborations — AstraZeneca (TEZSPIRE) Profit Share Recorded in Cost of Sales ($M) ($M)

Form 10-Q / 10-K Note 3 Collaborations (XBRL)

Latest, FY2025
587
Period ended Dec 31, 2025
Change on a year earlier
+42.5%
412 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCollaborations — AstraZeneca (TEZSPIRE) Profit Share Recorded in Cost of Sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025587+42.5%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 2024412+32.9%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 2023310+160.5%Form 10-K (filed 2026-02-13) ↗
FY2022Dec 31, 2022119–Form 10-K (filed 2025-02-14) ↗

Breakdown

What makes up collaborations — astrazeneca (tezspire) profit share recorded in cost of sales ($m)

Cite this data

StockData. (2026). Amgen Collaborations — AstraZeneca (TEZSPIRE) Profit Share Recorded in Cost of Sales ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/collab_az_cos

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.